XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Operations and Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Research and Development Expense, Gross $ 8,042 $ 7,316
Customer Funded Research and Development Expense Included in Cost of Goods Sold $ 1,216 $ 1,369
Weighted Average Number Diluted Shares Outstanding Adjustment, Total (in shares)   193,568
Restricted Stock [Member]    
Incremental Common Shares Attributable to Share-based Payment Arrangements, Total (in shares) 0 26,665
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 11,664  
Share-based Payment Arrangement, Option [Member]    
Incremental Common Shares Attributable to Share-based Payment Arrangements, Total (in shares) 0 526,244
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1,306,824 690,919
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Large Defense Primary Contractor, 1 [Member]    
Concentration Risk, Percentage 20.00% 17.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Large Defense Primary Contractor, 1 [Member] | Battery & Energy Products Segment [Member]    
Concentration Risk, Percentage 22.00%  
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Two Customers [Member] | Battery & Energy Products Segment [Member]    
Concentration Risk, Percentage   20.00%